Immunoglobulin Therapy and Standards of Practice
Clarke, Amy E. DNP, RN, IgCN®; Sobolevsky, Luba PharmD, IgCP® Home Healthcare Now 43(2):p 69-77, March/April 2025. | DOI: 10.1097/NHH.0000000000001330 Abstract: Immunoglobulin (Ig) therapy is vital for managing immunodeficiency and autoimmune disorders, offering...
Immunoglobulin National Society Appoints Amy E. Clarke, DNP, RN, IgCN®, as Chief Clinical Officer
The Immunoglobulin National Society (IgNS) has appointed Amy E. Clarke, DNP, RN, IgCN®, as its Chief Clinical Officer. A nationally recognized leader in immunoglobulin therapy with over 30 years of expertise, Dr. Clarke will drive clinical standards, research, and...
After the Storm
In order to prepare for any potential future crises, we must understand and learn from our current experiences. We appreciate this opportunity to get your feedback. Your opinion matters, and collectively, we can enact positive change in our healthcare industry.
Nufactor Pharmacists are Recognized as First to Achieve IgCP® Credential
Nufactor’s California Pharmacy Recognized as First Pharmacy to Achieve Immunoglobulin National Society’s (IgNS) Ig Certified Pharmacist (IgCP®) Credentialing TEMECULA, Calif. – Nufactor, Inc., a subsidiary of FFF Enterprises, Inc. is pleased to be recognized as...
#ItsMyTurn: IgNS Plasma Donation Initiative
During this unprecedented time of fear and uncertainty, we witness daily the incredible sacrifices of healthcare professionals, EMS, military, law enforcement, and others working tirelessly to keep patients healthy and save lives. We have witnessed people coming...
IgNS COVID-19 Resource Guide & FAQ
IgNS places the utmost importance on maintaining the health and safety of patients and healthcare providers during this COVID-19 global pandemic. IgNS has compiled relevant guidance to support clinicians and patients through the complexities of managing Ig patients...
Good news: R&D Progress Report on COVID-19
Coronavirus vaccine trial administers first doses to participants A Phase 1 clinical trial evaluating an investigational vaccine designed to protect against coronavirus disease 2019 (COVID-19) has begun at Kaiser Permanente Washington Health Research Institute...
Important IgNS Update (3/17/2020)
Dear Colleagues, IgNS is closely following the developments regarding the COVID-19 pandemic. This is a rapidly evolving situation, with information and guidance updated on an ongoing basis to reflect the most recent recommendations. Please check for updates from the...
COVID-19 Update
COVID-19 Update IgNS thanks all healthcare professionals and service providers, first responders, government agencies, and the healthcare industry who are working tirelessly in the face of the COVID-19 pandemic. Roche receives emergency approval for COVID-19...
IgNS Statement Regarding the Novel Coronavirus (COVID-19 or SARS-CoV-2)
IgNS Statement Regarding the Novel Coronavirus (COVID-19 or SARS-CoV-2) The recent outbreak of the 2019 Novel Coronavirus (COVID-19 or SARS-CoV-2) has raised awareness around the safety of plasma protein therapies in the US and worldwide. COVID-19 (or...
Stay In The Know
Join to receive important new, updates, and announcements.
Subscribe to Our Mailing List
© IgNS Copyright 2023 - All Rights Reserved
© IgNS Copyright 2024 - All Rights Reserved